HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beiersdorf sales

This article was originally published in The Rose Sheet

Executive Summary

Nivea generated $2.75 bil. (€1=$1.06) in 2002, fueling 7.2% gain in Beiersdorf's Cosmed division, German company announces in 1preliminary 2002 sales and earnings release Jan. 15. Cosmed division sales reached $3.35 bil., and earnings before interest and taxes increased approximately 13%, Beiersdorf says. Consolidated sales increased 4.4% to $5.02 bil., and after tax profit was $303.5 mil., an increase of approximately 23.7%. Endorsement of the financial statement by a supervisory board is scheduled for mid March, and Beiersdorf's annual press conference will be held April 2...

You may also be interested in...



Beiersdorf Goal For Nivea Includes 250 Market-Leading Positions By 2006

Beiersdorf's expansion plans for Nivea call for capturing 250 market-leading positions worldwide by 2006, the German firm said in its Feb. 5 1year-end sales release

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010888

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel